A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2023-06-25
Adverse events
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-10-25 (study day 103); relationship: N
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-01-23 (study day 193); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-02-04 (study day 205); relationship: not assessed
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-04-15 (study day 276); relationship: not assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2024-07-13 (study day 365); relationship: N
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-07-15 (study day 367); relationship: not assessed
Data queries
No data queries.